Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study - Maertens,J.A.; Thompson,G.R.; Spec,A.; Donovan,F.M.; Hammond,S.P.; Bruns,A.H.W.; Rahav,G.; Shoham,S.; Johnson,R.; Rijnders,B.; Schaenman,J.; Hoenigl,M.; et al. (The Lancet Infectious Diseases, 2025)